Sleep testing and management service provider Wesper has secured approval from the US Food and Drug Administration (FDA) for its next-generation sleep care device.
The new Wesper Lab patch is claimed to be the first and only platform to gather significant clinical-grade longitudinal data over multiple nights to monitor treatment efficacy, as well as diagnose and titrate, over time.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the company, the new device will also help significantly lower the operational burden for professionals that screen, diagnose and manage treatment.
Sleep testing is a crucial component in the diagnosis and treatment of sleep disorders such as sleep apnoea, as well as for minimising the risk of comorbid conditions, including dementia and heart disease.
Each patient will generally undergo a sleep test, which is said to take a lot of time and is also costly.
The company’s new approach is expected to help avoid these challenges by allowing the reuse of a single sleep test for several patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, its approach was trialled and validated through clinical studies.
Wesper CEO Amir Reuveny said: “Our commitment to innovation and quality is paving the way for sleep clinics to provide a better experience to their patients with high-fidelity data and insights.
“Our technology revolutionises sleep care by making sleep management more accessible and affordable for patients while also reducing waste and lowering costs for healthcare providers.”
